Satvam Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 2.31 Cr
as on 23-10-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.00 Cr
as on 23-10-2024
- Revenue 19.67%
(FY 2023)
- Profit -77.10%
(FY 2023)
- Ebitda 3.05%
(FY 2023)
- Net Worth -2.40%
(FY 2023)
- Total Assets 49.76%
(FY 2023)
About Satvam Pharma
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.31 Cr.
The company currently has active open charges totaling ₹20.00 Cr.
Chandan Soni, Anup Tapadiya, and Priyank Savani serve as directors at the Company.
- CIN/LLPIN
U24304MH2019PTC335058
- Company No.
335058
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2019
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Social Media-
Who are the key members and board of directors at Satvam Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandan Soni  | Director | 26-Dec-2019 | Current |
| Anup Tapadiya | Director | 26-Dec-2019 | Current |
| Priyank Savani | Director | 26-Dec-2019 | Current |
Financial Performance and Corporate Structure Insights of Satvam Pharma.
Satvam Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.67% increase. The company also saw a substantial fall in profitability, with a 77.1% decrease in profit. The company's net worth dipped by a decrease of 2.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satvam Pharma?
In 2023, Satvam Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tapadiya Interventional Technologies & H Ealthcare LlpActive 7 years 11 monthsAnup Tapadiya is a mutual person
Alicon Pharmaceutical Private LimitedActive 29 years 9 monthsChandan Soni, Anup Tapadiya and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 26 Mar 2024 | ₹1.00 Cr | Open |
Bank Of India Creation Date: 26 Mar 2024 | ₹19.00 Cr | Open |
How Many Employees Work at Satvam Pharma?
Satvam Pharma has a workforce of 7 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satvam Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satvam Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
